Cargando…
Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients
The coronavirus disease 2019 (COVID-19) emerged around December 2019 and have become a global epidemic disease currently. Specific antibodies against SAS-COV-2 could be detected in COVID-19 patients’ serum or plasma, but the clinical values of these antibodies as well as the effects of clinical drug...
Autores principales: | Wei, Liwen, Shang, Yuqi, Liu, Xi, Li, Xinghua, Chen, Gongqi, Liang, Siping, Zou, Zhengyu, Ding, Tao, Hong, Zhongsi, Wu, Minhao, Xia, Jinyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220093/ https://www.ncbi.nlm.nih.gov/pubmed/34177879 http://dx.doi.org/10.3389/fimmu.2021.580989 |
Ejemplares similares
-
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study
por: Liu, Xi, et al.
Publicado: (2020) -
Risk factors for the COVID‐19 severity and its correlation with viral shedding: A retrospective cohort study
por: Zheng, Xinchun, et al.
Publicado: (2020) -
Triggering Receptors Expressed on Myeloid Cells 2 Promotes Corneal Resistance Against Pseudomonas aeruginosa by Inhibiting Caspase-1-Dependent Pyroptosis
por: Qu, Wenting, et al.
Publicado: (2018) -
Clinical Time Features and Chest Imaging of 85 Patients With COVID-19 in Zhuhai, China
por: Liu, Zhuobing, et al.
Publicado: (2020) -
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)